Tislelizumab plus chemotherapy vs. pembrolizumab plus chemotherapy for the first-line treatment of advanced non-small cell lung cancer: systematic review and indirect comparison of randomized trials

Andrea Messori, Melania Rivano, Marco Chiumente, Daniele Mengato